CUSIP: 88338TAB0
What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Open recent reporting periods for CUSIP 88338TAB0:
As of 31 Dec 2025, 1 institutional investors reported holding $1 in principal (par value) of THERAVANCE INC - CORPORATE OBLIG.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $1 | $1 | 100.0% | 1 | |
| 2025 Q3 | $1 | $1 | 100.0% | 1 | |
| 2025 Q2 | $1 | $1 | 100.0% | 1 | |
| 2025 Q1 | $1 | $1 | 100.0% | 1 | |
| 2024 Q4 | $1 | $1 | 100.0% | 1 | |
| 2024 Q3 | $1 | $1 | 100.0% | 1 | |
| 2024 Q2 | $1 | $1 | 100.0% | 1 | |
| 2024 Q1 | $1 | $1 | 100.0% | 1 | |
| 2023 Q4 | $1 | $1 | 100.0% | 1 | |
| 2023 Q3 | $1 | $1 | 100.0% | 1 | |
| 2023 Q2 | $1 | $1 | 100.0% | 1 | |
| 2023 Q1 | $1 | $1 | -$96,256,967 | 100.0% | 1 |
| 2022 Q4 | $96,265,501 | $96,256,968 | -$20,425,493 | 99.88% | 19 |
| 2022 Q3 | $94,480,075 | $93,134,124 | -$4,005,066 | 98.53% | 18 |
| 2022 Q2 | $101,891,500 | $100,823,653 | +$10,989,918 | 98.71% | 18 |
| 2022 Q1 | $80,940,950 | $89,502,134 | -$157,659,342 | 110.55% | 17 |
| 2021 Q4 | $222,446,567 | $244,537,903 | +$32,094,408 | 109.21% | 23 |
| 2021 Q3 | $228,465,283 | $247,575,836 | +$9,581,356 | 107.51% | 31 |
| 2021 Q2 | $219,559,083 | $223,823,303 | -$14,403,472 | 101.63% | 26 |
| 2021 Q1 | $214,052,583 | $215,080,235 | -$13,282,274 | 100.43% | 25 |
| 2020 Q4 | $225,732,460 | $228,701,042 | -$872,650 | 99.84% | 26 |
| 2020 Q3 | $231,335,500 | $221,917,848 | +$3,985,755 | 95.84% | 28 |
| 2020 Q2 | $231,782,480 | $233,348,280 | +$483,783 | 99.14% | 27 |
| 2020 Q1 | $235,967,348 | $221,284,490 | -$1,394,947 | 93.13% | 30 |
| 2019 Q4 | $226,932,471 | $230,037,109 | +$409,851 | 100.48% | 26 |
| 2019 Q3 | $226,078,216 | $214,373,921 | -$3,693,932 | 93.88% | 24 |
| 2019 Q2 | $231,305,180 | $244,594,124 | -$8,478,868 | 105.02% | 23 |
| 2019 Q1 | $239,033,006 | $244,473,552 | +$9,256,895 | 101.59% | 24 |
| 2018 Q4 | $227,474,261 | $245,819,008 | -$15,927,276 | 108.0% | 27 |
| 2018 Q3 | $213,176,006 | $216,921,563 | +$7,886,593 | 101.38% | 29 |
| 2018 Q2 | $206,163,706 | $199,732,839 | +$6,940,927 | 97.03% | 33 |
| 2018 Q1 | $196,713,971 | $212,680,430 | +$14,289,892 | 107.2% | 35 |
| 2017 Q4 | $184,115,604 | $183,653,201 | -$17,575,315 | 99.11% | 35 |
| 2017 Q3 | $203,018,692 | $198,273,884 | -$31,617,856 | 97.58% | 29 |
| 2017 Q2 | $239,426,000 | $218,426,000 | +$2,473,611 | 91.33% | 33 |
| 2017 Q1 | $236,692,000 | $224,829,000 | +$9,740,981 | 94.92% | 28 |
| 2016 Q4 | $227,849,000 | $192,732,000 | -$3,694,326 | 85.0% | 21 |
| 2016 Q3 | $232,331,000 | $195,448,000 | +$6,852,179 | 84.25% | 20 |
| 2016 Q2 | $224,230,676 | $181,243,000 | -$14,853,509 | 80.17% | 18 |
| 2016 Q1 | $242,824,000 | $192,369,000 | +$691,504 | 78.97% | 20 |
| 2015 Q4 | $317,869,000 | $240,540,000 | +$2,750,149 | 75.15% | 22 |
| 2015 Q3 | $274,528,000 | $182,612,000 | +$17,956,923 | 66.07% | 24 |
| 2015 Q2 | $243,585,000 | $231,464,000 | -$4,323,541 | 93.9% | 25 |
| 2015 Q1 | $250,282,000 | $214,932,000 | -$1,541,621 | 84.99% | 23 |
| 2014 Q4 | $254,680,000 | $198,744,000 | -$10,047,473 | 78.23% | 23 |
| 2014 Q3 | $250,361,000 | $238,484,000 | -$44,353,412 | 95.49% | 21 |
| 2014 Q2 | $255,182,000 | $369,025,000 | +$8,085,450 | 144.2% | 21 |
| 2014 Q1 | $280,739,000 | $363,040,000 | +$13,398,317 | 128.89% | 25 |